Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...
(StatePoint) For Barb, who has been living with bronchiectasis for nearly 20 years, shortness of breath and an uncontrollable cough were a part of her daily life. She knew something was wrong because ...
Non–cystic fibrosis bronchiectasis (NCFB) is a chronic inflammatory condition of the lungs associated with respiratory infections and daily cough and sputum. Non-cystic fibrosis bronchiectasis. Image ...
Treatment with brensocatib 10 mg and 25 mg significantly reduced the annual rate of pulmonary exacerbations in patients with NCFB. The Food and Drug Administration (FDA) has approved Brinsupri ™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results